Literature DB >> 26010780

Detection of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis in infertile Bulgarian men with multiplex real-time polymerase chain reaction.

Vessela Ouzounova-Raykova1, Simeon Rangelov2, Iordanka Ouzounova2, Ivan Mitov1.   

Abstract

The effect of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis over the sperm quality is still unclear. The aim of this study was to determine their prevalence in infertile Bulgarian men. A total of 281 men were examined by applying mRT-PCR. The registered prevalence was as follows: C. trachomatis - 13.9%, U. urealyticum - 19.2%, M. hominis - 9.9%. Co-infection was established in eight swabs. This first in Bulgaria to study for detection of chlamydia and mycoplasmas in infertile men by mRT-PCR demonstrates higher prevalence of the tested microorganisms in the infertile group toward the control one.
© 2015 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Chlamydia; Mycoplasmas; infertile men; mRT-PCR; prevalence

Mesh:

Substances:

Year:  2015        PMID: 26010780     DOI: 10.1111/apm.12391

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  2 in total

1.  Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis.

Authors:  Daria A Burmistrova; Sergey V Tillib; Dmitry V Shcheblyakov; Inna V Dolzhikova; Dmitry N Shcherbinin; Olga V Zubkova; Tatiana I Ivanova; Amir I Tukhvatulin; Maxim M Shmarov; Denis Y Logunov; Boris S Naroditsky; Aleksandr L Gintsburg
Journal:  PLoS One       Date:  2016-03-10       Impact factor: 3.240

2.  Analysis of Ureaplasma urealyticum, Chlamydia trachomatis, Mycoplasma genitalium and Neisseria gonorrhoeae infections among obstetrics and gynecological outpatients in southwest China: a retrospective study.

Authors:  Ting Liu; Shu-Yu Lai; Wei Zhou; Yan-Ling Liu; Sha-Sha Chen; Yong-Mei Jiang
Journal:  BMC Infect Dis       Date:  2022-03-25       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.